What's Happening?
Corcept Therapeutics Incorporated, a company specializing in the development of medications that modulate cortisol effects, is set to present new data from its Phase 3 ROSELLA trial at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The trial investigates the efficacy of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer who have previously been treated with a PARP inhibitor. This patient group typically faces a poor prognosis. The presentation is scheduled for October 19, 2025, and will be part of a mini oral session on gynecological cancers. The ROSELLA trial is conducted in collaboration with several international oncology groups, including The GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG.
Why It's Important?
The presentation of new data from the ROSELLA trial is significant as it addresses a critical need for effective treatments in platinum-resistant ovarian cancer, a condition with limited options and poor survival rates. Relacorilant, a selective glucocorticoid receptor antagonist, offers a novel approach by modulating cortisol activity, which is known to contribute to tumor growth and chemotherapy resistance. The trial's findings could potentially lead to improved therapeutic strategies for approximately 20,000 women in the U.S. annually who are candidates for new treatments. Success in this trial could also bolster Corcept's position in the oncology market and expand its portfolio of cortisol-modulating therapies.
What's Next?
Following the presentation at ESMO, Corcept Therapeutics will await the FDA's decision on the Prescription Drug User Fee Act (PDUFA) date set for July 11, 2026, regarding relacorilant's use in treating platinum-resistant ovarian cancer. Positive trial results could lead to regulatory approval and subsequent commercialization, providing a new treatment option for patients. The company may also continue to explore relacorilant's application in other serious disorders, potentially broadening its impact in the medical field.
Beyond the Headlines
The development of relacorilant highlights the growing interest in cortisol modulation as a therapeutic strategy in oncology. This approach not only targets tumor growth but also addresses the body's immune response, offering a multifaceted treatment avenue. The success of such therapies could lead to a paradigm shift in cancer treatment, emphasizing hormone modulation alongside traditional chemotherapy.
